Subcutaneous efgartigimod PH20 SC is effective and tolerable for the treatment of CIDP, providing a convenient alternative to intravenous and other older treatments.
Medscape Medical News
First Treatment in 30 Years for Rare Disease Safe, Effective- First Treatment in 30 Years for Rare Disease Safe, Effective * First Treatment in 30 Years for Rare Disease Safe, Effective | First Treatment in 30 Years for Rare Disease Safe, Effective | First Treatment in 30 Years for Rare Disease Safe, Effective | First Treatment in 30 Years for Rare Disease Safe, Effective | First Treatment in 30 Years for Rare Disease Safe, Effective | First Treatment in 30 Years for Rare Disease Safe, Effective | First Treatment in 30 Years for Rare Disease Safe, Effective | First Treatment in 30 Years for Rare Disease Safe, Effective | | First Treatment in 30 Years for Rare Disease Safe, Effective | | First Treatment in 30 Years for Rare Disease Safe, Effective | | First Treatment in 30 Years for Rare Disease Safe, Effective |
